1H-苯并咪唑-4,7-二酮 | 7711-39-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1H-苯并咪唑-4,7-二酮
• 英文名称: benzimidazole-4,7-dione
• 英文别名: benzimidazolequinone；1H-benzoimidazole-4,7-dione；1H-benzimidazole-4,7-dione；1H-Benzimidazol-4,7-dion；benzimidazol-4,7-dione；Benzimidazol-chinon-(4,7)；4,7-Benzimidazoledione；1H-benzimidazole-4,7-dione
• CAS: 7711-39-9
• 化学式: C₇H₄N₂O₂
• 分子量: 148.121
• InChiKey: UVXXFOQQHBSTIC-UHFFFAOYSA-N

物化性质

• 沸点：
  483.9±45.0 °C(Predicted)
• 密度：
  1.574±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1H-苯并咪唑-4,7-二酮 生成 4,7-diacetoxy-1-acetyl-1H-benzoimidazole
  参考文献：
  名称：

  ISITOKU, TAKEHSI;IMUDA, DZYUNITI;TAKAXASI, KATSUYA

  摘要：

  DOI：
• 作为产物：
  描述：

  3,6-dimethoxybenzene-1,2-diamine hydrochloride 在 氢溴酸 、 三氯化铁 作用下， 生成 1H-苯并咪唑-4,7-二酮
  参考文献：
  名称：

  Syntheses of Dimethoxybenzimidazoles, Dihydroxybenzimidazoles and Imidazo-p-benzoquinones

  摘要：

  DOI：

  10.1021/jo01092a017

文献信息

• Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds
  申请人：——

  公开号：US20030220245A1

  公开（公告）日：2003-11-27

  The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.

  这项发明涉及通过亲核加成反应形成的聚合生物材料。这些生物材料可以用于医疗治疗。
• Imidazobenzoquinones and composition for preventing or treating
  申请人：TheUpjohn Company

  公开号：US05506361A1

  公开（公告）日：1996-04-09

  There are provided pharmacologically active compounds which are highly effective to treat hypertension or congestive heart failure, and are well absorbed into the body and have long-lasting action. Thus, the present invention provides A compound represented by the general formula: ##STR1## or a pharmacologically acceptable ester or salt thereof, and a pharmaceutical composition for preventing or treating hypertension or congestive heart failure which comprises the compound as an active ingredient.

  提供了药理活性化合物，对治疗高血压或充血性心力衰竭非常有效，并且能够被身体充分吸收，并具有持久的作用。因此，本发明提供了一种由一般式表示的化合物：##STR1## 或其药理学上可接受的酯或盐，并且包括该化合物作为活性成分的用于预防或治疗高血压或充血性心力衰竭的药物组合物。
• Method for sterilization using in situ gelling materials
  申请人：Vernon Brent

  公开号：US20060148897A1

  公开（公告）日：2006-07-06

  A method for sterilizing a female or male patient is provided. The method comprises introducing into a reproductive duct of the patient a composition comprising a nucleophilic component, such as a thiol, and a component containing a conjugated unsaturated bond, such as an acrylate. The composition crosslinks within the reproductive duct. Within a female patient, the composition is introduced into one or both uterine tubes. The composition gels in the uterine tubes, thereby blocking the uterine tubes and preventing conception.

  提供了一种对女性或男性患者进行灭菌的方法。该方法包括将含有亲核成分（例如巯基）和含有共轭不饱和键（例如丙烯酸酯）的组分引入到患者的生殖管中。该组分在生殖管内交联。在女性患者中，该组分被引入到一个或两个子宫管中。该组分在子宫管中凝胶，从而阻塞子宫管并防止受孕。
• Compositions for tissue augmentation
  申请人：Kuros Biosurgery AG

  公开号：US20030232944A1

  公开（公告）日：2003-12-18

  Methods for making biomaterials for augmentation of soft and hard tissues, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from at least a first and a second precursor component. The first precursor component contains at least two nucleophilic groups, and the second precursor component contains at least two electrophilic groups. The nucleophilic and electrophilic groups of the first and second precursor components form covalent linkages with each other at physiological temperatures. The precursors are selected based on the desired properties of the biomaterial. In the preferred embodiment, the first precursor is a siloxane. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to augment at least one vertebra of the spine (vertebroplasty).

  本文描述了用于增强软组织和硬组织的生物材料制备方法，包含形成生物材料的前体物质的套件以及所得到的生物材料。生物材料由至少第一和第二前体成分形成。第一前体成分含有至少两个亲核基团，第二前体成分含有至少两个电子亲和基团。第一和第二前体成分的亲核和电子亲和基团在生理温度下形成共价键。前体物质根据所需的生物材料性质进行选择。在首选实施例中，第一前体是硅氧烷。可选地，生物材料包含添加剂，例如流变剂、放射性不透明剂或生物活性剂。在首选实施例中，生物材料用于增强脊柱的至少一个椎体（椎体成形术）。
• COMPOSITIONS FOR TISSUE AUGMENTATION
  申请人：Molenberg Aaldert Rens

  公开号：US20100034769A1

  公开（公告）日：2010-02-11

  Methods for making biomaterials for augmentation of soft and hard tissues, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from at least a first and a second precursor component. The first precursor component contains at least two nucleophilic groups, and the second precursor component contains at least two electrophilic groups. The nucleophilic and electrophilic groups of the first and second precursor components form covalent linkages with each other at physiological temperatures. The precursors are selected based on the desired properties of the biomaterial. In the preferred embodiment, the first precursor is a siloxane. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to augment at least one vertebra of the spine (vertebroplasty).

  本文描述了用于增强软组织和硬组织的生物材料制备方法，包含形成生物材料的前体物质的套件，以及所得到的生物材料。生物材料由至少一个第一前体组分和一个第二前体组分形成。第一前体组分含有至少两个亲核基团，第二前体组分含有至少两个电离基团。第一和第二前体组分的亲核和电离基团在生理温度下形成共价键。前体物质的选择基于所需生物材料的性质。在首选实施例中，第一前体是硅氧烷。可选地，生物材料含有添加剂，例如流变剂、放射性不透明剂或生物活性剂。在首选实施例中，生物材料用于增强脊柱的至少一个椎体（椎体成形术）。